Stock comparison
ELI LILLY & Co is 713.4x more valuable than ArriVent BioPharma, Inc. by market capitalization ($1.119 T vs $1.57 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
LLY is larger
ELI LILLY & Co is 713.4x more valuable than ArriVent BioPharma, Inc. by market capitalization ($1.119 T vs $1.57 B).
Market value leader
LLY
ELI LILLY & Co is 713.4x more valuable than ArriVent BioPharma, Inc. by market capitalization ($1.119 T vs $1.57 B).
Profit leader
LLY
AVBP: -$166.31M vs LLY: $20.64B.
| Metric | AVBP | LLY |
|---|---|---|
| Market cap | $1.57 B | $1.119 T |
| US-listed rank | #2330 | #10 |
| Revenue (latest FY) | - | $65.18B |
| Net income (latest FY) | -$166.31M | $20.64B |
| Net margin | - | 31.7% |
| P/E (trailing FY) | - | 54.2x |
| SEC filings | 144 | 1,000 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
ELI LILLY & Co is 713.4x more valuable than ArriVent BioPharma, Inc. by market capitalization ($1.119 T vs $1.57 B).
Full pages: ArriVent BioPharma, Inc. and ELI LILLY & Co, or browse the full rankings.